Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays

References

• Galazka AM. Module 4: pertussis. WHO/EPI/GEN/93.14 ed. WHO; Geneva, Switzerland: 1996
   Google Scholar
• WHO. Expanded programme on immunisation, Global Advisory Group Meeting. Wkly Epidemiol Rec 1992;67:11-14
   PubMedGoogle Scholar
• WHO. Expanded programme on immunisation, Global Advisory Group Meeting. Wkly Epidemiol Rec 1992;67:17-19
   PubMedGoogle Scholar
• WHO. Pertussis surveillance. WHO/V&B/01.19 ed. WHO; Geneva, Switzerland: 2001
   Google Scholar
• WHO. Recommendations for whole-cell pertussis vaccine. WHO Technical Report Series 941. WHO; Geneva, Switzerland: 2007. p. 301-33
   Google Scholar
• Campbell P, McIntyre P, Quinn H, et al. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One 2012;7(4):e35874
   PubMedGoogle Scholar
• Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr 2012;161(6):1091-6
   PubMed Web of Science ®Google Scholar
• van der Maas NA, Mooi FR, de Greeff SC, et al. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine 2013;31(41):4541-7
   PubMed Web of Science ®Google Scholar
• Kmietowicz Z. Pertussis cases rise 10-fold among older children and adults in England and Wales. BMJ 2012;345:e5008
   PubMedGoogle Scholar
• Stainer DW, Scholte MJ. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol 1970;63(2):211-20
   PubMedGoogle Scholar
• Guiso N, von Konig CH, Becker C, Hallander H. Fimbrial typing of Bordetella pertussis isolates: agglutination with polyclonal and monoclonal antisera. J Clin Microbiol 2001;39(4):1684-5
   PubMedGoogle Scholar
• Xing DK, Ramakrishnan S, Newland P, Corbel MJ. Fimbrial typing of Bordetella pertussis isolates: agglutination with polyclonal and monoclonal antibodies. J Clin Microbiol 2001;39(11):4220
   PubMedGoogle Scholar
• van der Ark AA, Hozbor DF, Boog CJ, et al. Resurgence of pertussis calls for re-evaluation of pertussis animal models. Expert Rev Vaccines 2012;11(9):1121-37
   PubMed Web of Science ®Google Scholar
• Madsen T. Vaccination against whooping cough. J Am Med Assoc 1933;101:187-8
   Google Scholar
• McFarlan AM, Topley E, Fisher M. Trial of whooping-cough vaccine in city and residential nursery groups. Br Med J 1945;2(4415):205-8
   PubMedGoogle Scholar
• Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th edition. Elsevier; PA, USA: 2012
   Google Scholar
• Leslie PH, Gardner AD. The phases of Haemophilus pertussis. J Hyg (Lond) 1931;31(3):423-34
   PubMedGoogle Scholar
• Weiss AA, Falkow S. Genetic analysis of phase change in Bordetella pertussis. Infect Immun 1984;43(1):263-9
   PubMedGoogle Scholar
• Kendrick PL, Eldering G. Significance of bacteriological methods in the diagnosis and control of whooping cough. Am J Public Health Nations Health 1935;25(2):147-55
   PubMedGoogle Scholar
• Marks HM. The Kendrick-Eldering-(Frost) pertussis vaccine field trial. J R Soc Med 2007;100(5):242-7
   PubMedGoogle Scholar
• Marks HM. The Kendrick-Eldering-(Frost) pertussis vaccine field trial. JLL Bulletin: Commentaries on the history of treatment evaluation. 2006. Available from: www.jameslindlibrary.org
   Google Scholar
• Kendrick PL, Eldering G. A study on active immunisation against pertussis. Am J Hyg (Sect B) 1939;29:133-53
   Google Scholar
• Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for challenge. Am J Public Health Nations Health 1947;37(7):803-10
   Web of Science ®Google Scholar
• Medical Research Council. The prevention of whooping cough by vaccination. Br Med J 1951;1:1463-71
   PubMedGoogle Scholar
• Medical Research Council. Vaccination against whooping-cough; relation between protection in children and results of laboratory tests. Br Med J 1956;2(4990):454-62
   PubMedGoogle Scholar
• Medical Research Council. Vaccination against whooping-cough; the final report to the Whooping-Cough Immunization Committee of the Medical Research Council. Br Med J 1959;1(5128):994-1000
   PubMedGoogle Scholar
• WHO. Requirements for pertussis vaccine. WHO Technical Report Series 274. WHO; Geneva, Switzerland: 1964. p. 25-40
   Google Scholar
• Corbel MJ, Xing DK. The current status of acellular pertussis vaccines. J Med Microbiol 1997;46(10):817-18
   PubMedGoogle Scholar
• Jefferson T. Why the MRC randomized trials of whooping cough (pertussis) vaccines remain important more than half a century after they were done. JLL Bulletin: Commentaries on the history of treatment evaluation. The James Lind Library. 2006. Available from: www.jameslindlibrary.org
   Google Scholar
• Xing D, Das RG, O’Neill T, et al. Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test. Vaccine 2001;20(3-4):342-51
   PubMed Web of Science ®Google Scholar
• Berenbaum MC, Ungar J, Stevens WK. Intracranial infection of mice with Bordetella pertussis. J Gen Microbiol 1960;22:313-22
   PubMedGoogle Scholar
• Hopewell JW, Holt LB, Desombre TR. An electron-microscope study of intracerebral infection of mice with low-virulence Bordetella pertussis. J Med Microbiol 1972;5(1):154-7
   PubMedGoogle Scholar
• Robinson A, Hawkins DC. Structure and biological properties of solubilized envelope proteins of Bordetella pertussis. Infect Immun 1983;39(2):590-8
   PubMedGoogle Scholar
• Robinson A, Irons LI. Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice. Infect Immun 1983;40(2):523-8
   PubMedGoogle Scholar
• Xing D, Gaines DR, Douglas-Bardsley A, et al. An international collaborative study of the effect of active pertussis toxin on the modified Kendrick test for acellular pertussis vaccines. Biologicals 2014;42(2):101-8
   PubMedGoogle Scholar
• Xing DK, Canthaboo C, Corbel MJ. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo. Vaccine 2000;18(20):2110-19
   PubMedGoogle Scholar
• Canthaboo C, Xing D, Douglas A, Corbel M. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines. Biologicals 2000;28(4):241-6
   PubMedGoogle Scholar
• Mills KH. Immunity to Bordetella pertussis. Microbes Infect 2001;3(8):655-77
   PubMed Web of Science ®Google Scholar
• Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012;5(5):485-500
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases J. Minimum requirements for biological products. National Institute of Infectious Diseases; Japan: 2006
   Google Scholar
• Gaines-Das R, Horiuchi Y, Zhang SM, et al. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines. Vaccine 2009;27(49):6824-32
   PubMedGoogle Scholar
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. 8th edition. People’s Medical Publishing House; China: 2005
   Google Scholar
• Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996;334(6):341-8
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334(6):349-55
   PubMed Web of Science ®Google Scholar
• Heininger U, Cherry JD, Christenson PD, et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine 1994;12(1):81-6
   PubMedGoogle Scholar
• Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15(15):1606-12
   PubMed Web of Science ®Google Scholar
• Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333(16):1045-50
   PubMed Web of Science ®Google Scholar
• Assay of pertussis vaccine (whole cell). European Pharmacopeia. 8th edition. 2013. p. 242
   Google Scholar
• Pertussis vaccine. US Code of Federal Regulations. Washingon DC, USA, Government Printing Office, 1983. p. 58-61
   Google Scholar
• Sesardic D, Dawes CS, Mclellan K, Durrani Z, Yost SE, Corbel MJ. Non-pertussis components of combination vaccines: problems with potency testing. Biologicals 1999 Jun; 27(2):177-81
   PubMedGoogle Scholar
• Irwin JO, Standfast AF. The intracerebral mouse-protection test for pertussis vaccines. J Hyg (Lond) 1957;55(1):50-80
   PubMedGoogle Scholar
• Redhead K, Das RE. A collaborative assay of the proposed third British reference preparation for pertussis vaccine and of the relative potencies of the second International standard and the second British reference preparation for pertussis vaccine. Biologicals 1991;19(2):107-11
   PubMedGoogle Scholar
• Xing DK, Gaines DR, Newland P, Corbel M. Third International Standard for pertussis vaccine: international confirmation study of activity of British Standard for pertussis vaccine, coded 66/303. Biologicals 2001;29(2):133-6
   PubMedGoogle Scholar
• Das RG, Newland P, Asokanathan C, et al. Evaluation of fourth international standard for whole cell pertussis vaccine. Biologicals 2010;38(6):644-51
   PubMedGoogle Scholar
• Standfast AF. Some factors influencing the virulence for mice of Bordetella pertussis by the intracerebral route. Immunology 1958;1(2):123-34
   PubMedGoogle Scholar
• WHO. WHO manual for the establishment of national and other secondary standards for vaccines. WHO; Geneva, Switzerland: 2011
   Google Scholar
• Finney DJ. Probit analysis. Cambridge University Press; Cambridge, London, UK: 1952
   Google Scholar
• Pittman M. Instability of pertussis-vaccine component in quadruple antigen vaccine. Diphtheria and tetanus toxoids and pertussis and poliomyelitis vaccines. JAMA 1962;181:25-30
   PubMedGoogle Scholar
• WHO. Recommendations to assure the quality, safety and efficacy of DT-based combined vaccines. WHO Technical Report Series. 980 edition. WHO; Geneva, Switzerland: 2014. p. 335-406
   Google Scholar
• Park J, Zhang Y, Buboltz AM, et al. Comparative genomics of the classical Bordetella subspecies: the evolution and exchange of virulence-associated diversity amongst closely related pathogens. BMC Genomics 2012;13:545
   PubMed Web of Science ®Google Scholar
• Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001;7(3 Suppl):526-8
   PubMedGoogle Scholar
• He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol 2008;3(3):329-39
   PubMed Web of Science ®Google Scholar
• King AJ, van der Lee S, Mohangoo A, et al. Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains. PLoS One 2013;8(6):e66150
   PubMed Web of Science ®Google Scholar
• King AJ, Berbers G, van Oirschot HF, et al. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001;147(Pt 11):2885-95
   PubMedGoogle Scholar
• Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio 2014;5(2):e01074
   PubMed Web of Science ®Google Scholar
• Bart MJ, van Gent M, van der Heide HG, et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 2010;11:627
   PubMed Web of Science ®Google Scholar
• Corbel MJ, Xing DK. Toxicity and potency evaluation of pertussis vaccines. Expert Rev Vaccines 2004 Feb; 3(1):89-101
   PubMedGoogle Scholar
• Alternatives to whole-cell pertussis vaccine potency assay. In: European Directorate for the Quality of Medicines CoE, editor. EDQM Proceedings. Geneva, 2005.
   Google Scholar
• Mascart F, Verscheure V, Malfroot A, et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 2003;170(3):1504-9
   PubMed Web of Science ®Google Scholar
• Giammanco A, Taormina S, Chiarini A, et al. Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough. Vaccine 2003;21(17-18):1924-31
   PubMedGoogle Scholar
• Guiso N, Njamkepo E, Vie le Sage F, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007;25(8):1390-7
   PubMed Web of Science ®Google Scholar
• Schure RM, Hendrikx LH, de Rond LG, et al. T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. Clin Vaccine Immunol 2012;19(11):1879-86
   PubMedGoogle Scholar
• Melvin JA, Scheller EV, Miller JF, Cotter PA. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 2014;12(4):274-88
   PubMed Web of Science ®Google Scholar
• Guiso N, Capiau C, Carletti G, et al. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999;17(19):2366-76
   PubMed Web of Science ®Google Scholar
• Mills KH, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998;66(2):594-602
   PubMed Web of Science ®Google Scholar
• Sato H, Sato Y. Pertussis vaccine. In: Researcher’s associates TNIoH, editor. Vaccine handbook. Maruzen Co. Ltd; Tokyo, Japan: 1996. p. 39-51
   Google Scholar
• Syukuda Y, Watanabe H, Suehara A, et al. Aerosol infection test for evaluation of pertussis vaccine. Tokai J Exp Clin Med 1988;13(Suppl):71-7
   PubMedGoogle Scholar
• Denoel P, Poolman J, Carletti G, Veitch K. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine 2002;20(19-20):2551-5
   PubMedGoogle Scholar
• Godfroid F, Denoel P, de Grave D, et al. Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses. Int J Med Microbiol 2004;294(5):269-76
   PubMedGoogle Scholar
• Sato Y, Izumiya K, Sato H, et al. Aerosol infection of mice with Bordetella pertussis. Infect Immun 1980;29(1):261-6
   PubMedGoogle Scholar
• Petersen JW, Andersen P, Ibsen PH, et al. Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine. Vaccine 1993;11(4):463-72
   PubMedGoogle Scholar
• Corbel MJ, Kreeftenberg JG, Knezevic I. WHO Working Group on the standardisation and control of pertussis vaccines-report of a meeting held on 6-7 May 2003, Ferney Voltaire, France. Vaccine 2004;22(3-4):293-300
   PubMedGoogle Scholar
• Xing DK, Das RG, Williams L, et al. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 1999;17(6):565-76
   PubMedGoogle Scholar
• Warfel JM, Beren J, Merkel TJ. Airborne transmission of Bordetella pertussis. J Infect Dis 2012;206(6):902-6
   PubMed Web of Science ®Google Scholar
• Warfel JM, Beren J, Kelly VK, et al. Nonhuman primate model of pertussis. Infect Immun 2012;80(4):1530-6
   PubMed Web of Science ®Google Scholar
• Warfel JM, Papin JF, Wolf RF, et al. Maternal and neonatal vaccination protects newborn baboons from pertussis infection. J Infect Dis 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Canthaboo C, Xing D, Corbel M. Development of a nitric oxide induction assay as a potential replacement for the intracerebral mouse protection test for potency assay of pertussis whole cell vaccines. Dev Biol Stand 1999;101:95-103
   PubMedGoogle Scholar
• Sakurai S, Kamachi K, Konda T, et al. Nitric oxide induction by pertussis toxin in mouse spleen cells via gamma interferon. Infect Immun 1996;64(4):1309-13
   PubMed Web of Science ®Google Scholar
• von Hunolstein C, Gomez Miguel MJ, Pezzella C, et al. Evaluation of two serological methods for potency testing of whole cell pertussis vaccines. Pharmeur Bio 2008;2008(1):7-18
   PubMedGoogle Scholar
• van der Ark A, van Straaten-van de Kappelle I, Akkermans A, et al. Development of pertussis serological potency test. Serological assessment of antibody response induced by whole cell vaccine as an alternative to mouse protection in an intracerebral challenge model. Biologicals 1994;22(3):233-42
   PubMed Web of Science ®Google Scholar
• Matos DC, Marcovistz R, da Silva AM, et al. Comparative analysis of the intracerebral mouse protection test and serological method for potency assays of pertussis component in DTP vaccine. Braz J Microbiol 2012;43(2):429-31
   PubMed Web of Science ®Google Scholar
• van Straaten I, Levels L, van der Ark A, et al. Toxicity and immunogenicity of pertussis whole cell vaccine in one animal model. Dev Biol (Basel) 2002;111:47-55
   PubMedGoogle Scholar
• van der Ark A, van Straaten-van de Kappelle I, Hendriksen CF. Pertussis serological potency test as an alternative to the intracerebral mouse protection test: development, evaluation and validation. ALTEX 1998;15(5):33-6
   PubMedGoogle Scholar
• Website of the encyclopedia of life. 2014. Available from: www.eol.org [Last accessed on 20 Mar 2014]
   Google Scholar
• Website of the European Bioinformatics Institute. 2014. Available from: www.ebi.ac.uk [Last accessed 20 Mar 2014]
   Google Scholar
• Belcher CE, Drenkow J, Kehoe B, et al. The transcriptional responses of respiratory epithelial cells to Bordetella pertussis reveal host defensive and pathogen counter-defensive strategies. Proc Natl Acad Sci USA 2000;97(25):13847-52
   PubMedGoogle Scholar
• Boldrick JC, Alizadeh AA, Diehn M, et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci USA 2002;99(2):972-7
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009;10(1):116-25
   PubMed Web of Science ®Google Scholar
• Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011;12(8):786-95
   PubMed Web of Science ®Google Scholar